Erasca Upsizes Offering to $632.5M Amid Promising Pancreatic Cancer Data
ERAS has more than doubled off its 52-week low of $1.33.
Summary
Erasca raised $632.5M in an upsized follow-on offering at $17.50 per share, significantly above the initially planned $550M, signaling strong institutional demand. The raise comes alongside updated Phase 1 data for ERAS-0015 showing a 57% unconfirmed ORR in second-line KRAS G12X pancreatic cancer, with most responders still on treatment. The offering provides substantial runway for the company's R&D programs, including the ongoing AURORAS-1 trial and the recently announced Merck collaboration. This follows the July 13 data update and the July 14 initial pricing, with the upsized deal reflecting confidence in the asset's potential despite prior legal and safety overhangs.
At the time of this announcement, ERAS was trading at $18.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.7B. The 52-week trading range was $1.33 to $24.28. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.